scispace - formally typeset
H

Hualin Fu

Researcher at Sichuan Agricultural University

Publications -  111
Citations -  1350

Hualin Fu is an academic researcher from Sichuan Agricultural University. The author has contributed to research in topics: Solubility & Medicine. The author has an hindex of 15, co-authored 90 publications receiving 738 citations.

Papers
More filters
Journal ArticleDOI

Isobologram Analysis: A Comprehensive Review of Methodology and Current Research.

TL;DR: The principle of isobologram analysis and its application in drug interaction evaluation are summarized and the applications of the similar cotoxicity coefficient and fractional inhibitory concentration index in the evaluation of drug interaction are reviewed.
Journal ArticleDOI

Presence of zoonotic Cryptosporidium scrofarum, Giardia duodenalis assemblage A and Enterocytozoon bieneusi genotypes in captive Eurasian wild boars (Sus scrofa) in China: potential for zoonotic transmission.

TL;DR: This first report on the occurrence of Cryptosporidium, G. duodenalis and E. bieneusi in captive wild boar in China indicates that the presence of zoonotic species/assemblages/genotypes poses a threat to public health, and suggests that wild boars could be a significant source of human infection and water pollution.
Journal ArticleDOI

Epidemiology of Blastocystis sp. infection in China: a systematic review

TL;DR: Findings provide insights into the epidemiological behavior of Blastocystis sp.
Journal ArticleDOI

Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules

TL;DR: A broad overview of the targeting vectors and targeting pathways for renal tubules and glomeruli is provided, as well as how the unique structural features of the glomerulus and the receptor‐mediated internalization pathways of the tubules allows for drug targeting.
Journal ArticleDOI

Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells

TL;DR: Potential targeting strategies for renal cancer cells and renal CSCs are summarized, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors (mTOR), interleukins, CSC marker inhibitors, bone morphogenetic protein-2, antibody drug conjugates, and nanomedicine.